Welcome
Support Centre
10 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Eradication of Helicobacter pylori increases ghrelin production in the gastric mucosa
ISRCTN ISRCTN59881192
ClinicalTrials.gov identifier
Public title Eradication of Helicobacter pylori increases ghrelin production in the gastric mucosa
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis To investigate whether Helicobacter pylori eradication influences ghrelin/obestatin production and appetite.
Lay summary Not provided at time of registration
Ethics approval Institutional Review Board of Inje University, Ilsan-Paik Hospital, Clinical Research Center 05-12, South Korea. Date of approval: 28/10/2005
Study design Randomised controlled trial
Countries of recruitment Korea, South
Disease/condition/study domain Helicobacter pylori infection
Participants - inclusion criteria Healthy volunteers with H. pylori infection, who saw a poster describing the study and wanted to participate.
Participants - exclusion criteria 1. Age <20 or >70 years
2. Pregnancy
3. Abnormal gastric lesion, including ulcer and cancer
4. Duodenal ulcer
5. Liver disease
6. Renal impairment
7. Previous gastrointestinal surgery
8. History of H. pylori eradication
9. Drug abuse
Anticipated start date 17/02/2006
Anticipated end date 30/05/2006
Status of trial Completed
Patient information material
Target number of participants 30
Interventions The treatment group received a triple H. pylori eradication regimen consisting of 20 mg esomeprazole, 1,000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days. The control group received no medication.
Primary outcome measure(s) Ghrelin mRNA levels in gastric mucosa at baseline and 5 weeks
Secondary outcome measure(s) The following were assessed at baseline and 5 weeks:
1. Obestatin and TNF-a mRNA of gastric mucosa
2. Plasma ghrelin, obestatin and ghrelin/obestatin ratio
Sources of funding Inje University, Ilsan paik Hospital (Korea, South)
Trial website
Publications
Contact name Dr  Eon Sook  Lee
  Address 2240
Daewha-dong
Ilsanseo-gu
Goyang-si
  City/town Gyeonggi-do
  Zip/Postcode 411-706
  Country Korea, South
Sponsor Inje University, Ilsan Paik Hospital (Korea, South)
  Address 2240
Daewha-dong
Ilsanseo-gu
Goyang-si
  City/town Gyeonggi-do
  Zip/Postcode 411-706
  Country Korea, South
  Sponsor website: http://www.inje.ac.kr/english
Date applied 15/02/2008
Last edited 16/08/2011
Date ISRCTN assigned 10/03/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central